股票代码：002734 股票简称：利民股份 公告编号：2025-040 利民控股集团股份有限公司关于 2025 年 一季度计提信用减值损失及资产减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提资产减值损失和信用减值损失情况概述 公司根据《深圳证券交易所股票上市规则》《企业会计准则》等相关规定，本 着谨慎性原则，对 2025 年一季度末合并财务报表范围内的各项资产等进行了减值 测试，判断存在可能发生减值的迹象，确定了需要计提资产减值损失及信用减值损 失的资产项目。 根据评估和分析的结果判断，计提 2025 年一季度末各项资产减值损失 6,603,966.67 元，计提各项信用减值损失 13,921,534.63 元，具体情况如下： 单位：人民币元 | 类别 | 项目 | 计提金额 | | --- | --- | --- | | 资产减值损失 | 存货跌价损失 | 6,603,966.67 | | 信用减值损失 | 应收账款坏账损失 | 13,846,200.87 | | | 其他应收款坏账损失 | 75,333.76 | | | 合计 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,210,766,106.64, representing a 22.28% increase compared to ¥990,165,904.71 in the same period last year[5] - Net profit attributable to shareholders was ¥108,119,145.89, a significant increase of 1,373.23% from a loss of ¥8,491,731.94 in the previous year[5] - Basic earnings per share increased to ¥0.30, up 1,600.00% from -¥0.02 in the same quarter last year[5] - Total operating revenue for the current period reached ¥1,210,766,106.64, a significant increase from ¥990,165,904.71 in the previous period, representing a growth of approximately 22.3%[18] - Net profit for the current period was ¥114,051,569.50, a turnaround from a net loss of ¥6,078,360.23 in the previous period[19] - The total comprehensive income for the period attributable to the parent company's owners was CNY 108,084,899.84, a decrease of CNY 8,484,662.60 compared to the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 66.50%, amounting to -¥68,260,504.30, compared to -¥203,775,619.00 in the prior year[5] - Cash inflow from operating activities totaled CNY 616,156,251.45, compared to CNY 595,097,043.16 in the previous period[21] - Cash outflow from operating activities was CNY 684,416,755.75, down from CNY 798,872,662.16 in the previous period[22] - Cash flow from investing activities generated a net inflow of CNY 4,816,212.51, compared to a net outflow of CNY 37,115,367.19 in the previous period[22] - Cash flow from financing activities resulted in a net outflow of CNY 21,389,592.67, an improvement from negative CNY 52,481,775.67 in the previous period[22] - The ending cash and cash equivalents balance was CNY 377,094,281.59, an increase from CNY 300,301,357.98 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,627,733,937.10, a slight decrease of 0.49% from ¥6,660,284,764.42 at the end of the previous year[5] - Total liabilities decreased to ¥3,720,737,155.12 from ¥3,964,780,386.48, a reduction of approximately 6.2%[16] - The company's equity increased to ¥2,906,996,781.98 from ¥2,695,504,377.94, reflecting a growth of about 7.8%[16] Research and Development - The company's R&D expenses rose by 46.84%, indicating increased investment in research and development projects[9] - Research and development expenses rose to ¥43,184,020.29, compared to ¥29,407,900.00 in the previous period, indicating a growth of approximately 46.6%[19] Investment and Income - Investment income surged by 2,938.77%, reflecting changes in the profitability of the company's equity investments[9] - The company reported an investment income of ¥24,205,849.24, compared to a loss of ¥852,687.14 in the previous period, indicating a significant improvement[19] - The company received government subsidies amounting to ¥1,375,623.50, contributing to the increase in other income by 79.49%[9] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,313[11] - The largest shareholder, Li Ming, holds 20.01% of the shares, amounting to 73,734,050 shares, with 41,580,915 shares pledged[11] - Li Xinsong, the second-largest shareholder, owns 12.14% of the shares, totaling 44,737,620 shares, with 36,720,000 shares pledged[11] - The total number of preferred shareholders at the end of the reporting period is zero, indicating no preferred shares issued[12] Operational Highlights - The company's cash and cash equivalents decreased from 666,121,894.29 CNY to 572,953,087.71 CNY, a decline of approximately 14.1%[14] - Accounts receivable increased significantly from 369,992,859.18 CNY to 660,193,165.48 CNY, representing an increase of about 78.3%[14] - Inventory remained relatively stable, with a slight increase from 763,151,351.60 CNY to 764,207,168.33 CNY[14] - The company has been recognized as a "High-tech Enterprise," with the certificate number GR202415000195, valid for three years[12] - The company has obtained an investment project filing certificate from Jiangsu Province, indicating ongoing expansion efforts[12] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[19]

Core Viewpoint - Limin Co., Ltd. reported a significant increase in net profit for 2024, but faced cash flow pressure, highlighting a mixed financial performance [1][6]. Financial Performance - The company achieved total revenue of 4.237 billion yuan, a year-on-year increase of 0.32% [1]. - Net profit attributable to shareholders reached 813.576 million yuan, reflecting a year-on-year growth of 31.11% [1]. - Operating cash flow decreased by 20.70% year-on-year, amounting to 374 million yuan, indicating cash flow challenges [1][6]. Innovation and Brand Development - Limin Co., Ltd. made significant strides in technological innovation and brand building, being recognized in the green low-carbon process directory of the pesticide industry [4]. - Key technologies such as "continuous flow production process of aluminum phosphonate" and "gas-phase full-process continuous glyphosate production process" were highlighted [4]. - The brand "Limin Linghu" won the most explosive brand product award in the national plant protection market for fungicides [4]. R&D Investment and Project Implementation - The company invested 162 million yuan in R&D in 2024, a decrease of 4.5% year-on-year, but made notable progress in the conversion of innovative results [5]. - The establishment of a synthetic biology laboratory improved key technical indicators such as strain performance and biosynthesis efficiency [5]. - New projects, including 500 tons of cyclohexanone and 2,000 tons of glyphosate, were successfully launched, enhancing production capacity [5]. Cash Flow and Shareholder Pledge - The net cash flow from financing activities was -330 million yuan, a decrease of 175 million yuan year-on-year, exacerbating the company's financial strain [6]. - High levels of shareholder pledges were noted, with the largest shareholder pledging 41.5809 million shares (56.39% of total holdings) and the second-largest pledging 36.72 million shares (82.08% of total holdings) [6].

股票代码：002734 股票简称：利民股份 公告编号：2025-031 利民控股集团股份有限公司 关于 2025 年度向银行申请综合授信额度的公告 以上授信额度最终以各家银行实际审批的授信额度及期限为准，用途包括但不 限于流动资金借款、信用证、保函、银行票据等，具体融资金额将视公司及子公司 实际经营情况需求决定。授信期限内，授信额度可循环使用。 公司董事会提请股东大会授权公司董事长或其指定的授权代理人在本议案授 信额度范围内决定相关事宜并签署有关业务的具体文件（包括但不限于授信、借款、 抵押、担保、融资等有关的合同、协议、申请书等各项法律文件），由此产生的法 律、经济责任全部由公司承担。 本次申请银行综合授信额度尚需提交公司股东大会审议通过，议案有效期自本 议案经股东大会审议通过后起至 2025 年度股东大会审议相关议案之日止。 特此公告。 利民控股集团股份有限公司董事会 2024 年 04 月 17 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据利民控股集团股份有限公司（以下简称"公司"）及子公司生产经营和资 金使用计划的需要，同时长久保持与各银行 ...

股票代码：002734 股票简称：利民股份 公告编号：2025-034 利民控股集团股份有限公司 关于公司及子公司开展外汇衍生品业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 利民控股集团股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第 六届董事会第四次会议、第六届监事会第四次会议，审议通过了《关于公司及子公 司开展外汇衍生品业务的议案》，为降低汇率波动风险，根据公司业务发展情况， 同意公司及子公司开展外汇衍生品业务，董事会授权管理层在审议额度范围内根据 业务情况、实际需要审批外汇衍生品业务和选择合作银行。现就相关事宜公告如下： 一、开展外汇衍生品交易业务的原因和目的 公司及子公司国际贸易金额较大，为有效规避外汇市场的风险，防范汇率大幅 波动对公司业绩造成不良影响，提高外汇资金使用效率，合理降低财务费用，增强 公司财务稳健性。公司及子公司拟开展外汇衍生品交易业务，公司及子公司开展外 汇衍生品交易业务主要以套期保值为目的。 二、公司拟开展外汇衍生品交易业务的品种 公司及子公司拟开展的外汇衍生品是指远期、互换、期权等产品或上述产 ...

利民控股集团股份有限公司 关于 2024 年度会计师事务所履职情况评估报告 利民控股集团股份有限公司（以下简称"公司"）聘请天衡会计师事务所（特 殊普通合伙）（以下简称"天衡"）作为公司2024年度年报审计机构，根据财政部、 国资委及证监会颁布的《国有企业、上市公司选聘会计师事务所管理办法》等法律 法规的规定和要求，公司对天衡2024年度的履职情况进行了评估，具体情况如下： 一、资质条件 1、基本信息 首席合伙人：郭澳 2024年末，天衡会计师事务所（特殊普通合伙）合伙人85人，注册会计师386 人（较2023年末注册会计师（419人）减少33人），从事过证券服务业务的注册会 计师227人。 2024年度业务收入52,937.55万元，其中审计业务收入46,009.42万元、证券业 务收入15,518.61万元。 天衡会计师事务所（特殊普通合伙）为95家上市公司提供2023年报审计服务， 收费总额9,271.16万元，具有上市公司所在行业审计业务经验。天衡会计师事务所 （特殊普通合伙）客户主要集中于计算机、通信和其他电子设备制造业、化学原料 及化学制品制造业、医药制造业、通用设备制造业、专用设备制造业。 2、 ...

一、2024年度董事会履职概况 （一）规范公司治理 2024 年度董事会工作报告 利民控股集团股份有限公司 2024 年度董事会工作报告 《公司2023年度董事会工作报告》中明确指出，2024年主体工作指导思想为： "以市场为中心，以利润为导向，聚焦问题短板，合力攻坚克难，全面提升免疫力 和抗逆周期能力"。 2024年，公司董事会紧紧围绕这一核心目标，统筹战略规划与风险管控，深化 公司治理改革，推动公司高质量发展，取得了显著的成果。现将本年度履职情况汇 报如下： 2024年，全年召开董事会会议10次，审议议案58项，对调整战略规划、财务预 算、重大投资等重要事项作出决策。对外披露117份公告文件，向深圳证券交易所 报备文件149份。 2024年，公司董事会持续推动完善法人治理结构，制定了《独立董事专门会议 工作制度》，并完成《公司章程》《独立董事工作制度》《董事会审计委员会工作 细则》《提名委员会工作细则》《薪酬与考核委员会工作细则》《反舞弊制度》《商 业道德制度》等14项制度的修订，重点完善资金管理、关联交易、投资决策等流程， 强化审计委员会反舞弊职责；通过每月给独董发送内部信息月报，及时了解公司内 部运行 ...

利民控股集团股份有限公司 2024 年环境、社会与管治（ESG）报告 股票代码 002734 精于生物科技 创造品质生活 | 前篇 . | | --- | | (一) 报告编制说明 | | 1. 报告简介 | | 2. 报告范围 | | 3. 编制依据 | | 4. 数据来源 | | 5. 指代说明 | | 6. 可靠性保证 | | 7. 联系我们 | | (二) 董事长致辞 . | | (三) 走进利民…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 5 | | 1. 公司概况 | | 2. 企业文化 | | 3. 集团化管理 . | | 4. 市场竞争力 . | | 5. 经济绩效 | | ( 四 ) 责任荣誉 ……………………………………………………………………………………………………………………… 11 | | 1. 品牌领导力 . | | 2. 行业领先力 . | | 3. 可持续发展力 | | 4. 行业参与 | | (五) 董事会 ...

利民控股集团股份有限公司 股票代码：002734 股票简称：利民股份 公告编号：2025-032 为提高公司决策效率，满足子公司的经营发展需求，降低财务成本，公司拟向 经营活动中因向金融机构申请综合授信业务、贷款、保理业务、融资租赁业务等需 要母公司为子公司提供担保的业务提供担保，公司预计 2025 年度为合并报表范围 内的全资及控股子公司提供不超过人民币 189,000 万元的连带责任保证担保。 本次担保额度预计情况如下： 单位：万元 | 担 方 | 保 | 被担保人 名称 | 担保方 持股比 | 被担保方 最近一期 | 截至目前担 | 本次新增 | 担保额度占公 司最近一期净 | 是否 关联 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 例 | 资产负债 率 | 保余额 | 担保额度 | 资产比例 | 担保 | | 资产负债率 | | 70%以下 | | | | | | | | 公司 | | 利民化学 | 100% | 36.36% | 40,000.00 | 64,000 | 24.22% | 否 | | 公司 | | ...